OTCMKTS:BRTXQ BioRestorative Therapies (BRTXQ) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free BRTXQ Stock Alerts $1.23 -0.04 (-3.15%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.21▼$1.2850-Day Range$1.27▼$1.5052-Week Range$0.00▼$0.06Volume61,486 shsAverage Volume62.17 million shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get BioRestorative Therapies alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About BioRestorative Therapies Stock (OTCMKTS:BRTXQ)BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.Read More BRTXQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTXQ Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comWhy BioRestorative Therapies Is Rising In Pre-market?April 8, 2024 | msn.comBioRestorative Therapies partners with Galen Patient RecruitmentApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 3, 2024 | msn.comBioRestorative Therapies files to sell 2.51M shares of common stock for holdersMarch 12, 2024 | forbes.com5 Best Affordable Online Therapy Options Of 2024February 6, 2024 | msn.comBioRestorative Therapies tumbles after private placementFebruary 5, 2024 | markets.businessinsider.comBioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc DiseaseJanuary 12, 2024 | morningstar.comBioRestorative Therapies Inc BRTXApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.December 4, 2023 | money.usnews.comOccupational Therapy Assistant SalaryOctober 9, 2023 | nasdaq.comBioRestorative Therapies (FRA:9OF) Price Target Increased by 8.74% to 12.19September 1, 2023 | benzinga.comBioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are BuyingJuly 20, 2023 | benzinga.comBioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York StateJuly 11, 2023 | marketwatch.comBioRestorative Therapies Shares Lower Premarket on Stock Offering >BRTXJune 27, 2023 | benzinga.comEXCLUSIVE: BioRestorative Therapies Tells Benzinga Data Monitoring Committee Allows Co's Chronic Lumbar Disc Disease To Continue UnchangedJune 12, 2023 | benzinga.comBioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc DiseaseJune 12, 2023 | benzinga.comEXCLUSIVE: BioRestorative Completes Dosing In Safety Cohort Of Chronic Lower Back Pain TrialMay 31, 2023 | benzinga.comEXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell ProcessingMay 15, 2023 | msn.comEXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese PatentMarch 3, 2023 | marketwatch.comBioRestorative Therapies Shares Rise 40% After U.S. Patent AllowanceFebruary 26, 2023 | nbcnews.comWhat is red light therapy and does it work?January 25, 2023 | benzinga.com2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative TherapiesNovember 9, 2022 | benzinga.comThe NIH Has Given BioRestorative Therapies A Stamp Of ApprovalNovember 2, 2022 | stockhouse.comSee What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!September 9, 2022 | morningstar.comBioRestorative Therapies Inc BRTX Stock AnalysisJune 30, 2022 | msn.comBioRestorative Shares Fall As Enrolment Initiated in Mid-Stage Chronic Back Pain Drug StudyJune 14, 2022 | benzinga.comBioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)See More Headlines Receive BRTXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolOTCMKTS:BRTXQ CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales18,334.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-1.81Miscellaneous Outstanding Shares1,639,626,000Free FloatN/AMarket Cap$2.02 billion OptionableNot Optionable Beta102.36 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Mark R. Weinreb M.S. (Age 67)Chairman, CEO & Pres Comp: $407.2kMr. Robert Paccasassi (Age 51)VP of Quality & Compliance Comp: $233.95kMr. Francisco J. Silva (Age 45)Chief Scientist and VP of R&D Comp: $310.5kDr. Wayne J. OlanClinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsIntellia TherapeuticsNASDAQ:NTLACelldex TherapeuticsNASDAQ:CLDXAstrana HealthNASDAQ:ASTHKeros TherapeuticsNASDAQ:KROSRocket PharmaceuticalsNASDAQ:RCKTView All Competitors BRTXQ Stock Analysis - Frequently Asked Questions How have BRTXQ shares performed in 2024? BioRestorative Therapies' stock was trading at $1.7399 at the beginning of the year. Since then, BRTXQ stock has decreased by 29.3% and is now trading at $1.23. View the best growth stocks for 2024 here. How do I buy shares of BioRestorative Therapies? Shares of BRTXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BRTXQ) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.